Enanta Pharmaceuticals, Inc. — FY2014 Form 10-K
Reporting period: Fiscal year ended September 30, 2014. The filing also reports fourth-quarter results for the three months ended September 30, 2014. Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise indicated.
Business context
Enanta is a research-and-development-focused biotechnology company with no approved products or product-sale revenue. Its principal near-term financial opportunity depends on AbbVie’s development and commercialization of HCV protease inhibitors paritaprevir (ABT-450) and ABT-493. Enanta’s independent pipeline includes the NS5A inhibitor EDP-239 and preclinical cyclophilin and nucleotide-polymerase inhibitor programs.
Financial and operating results
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $47.741 | $32.053 |
| Research and development expense | $18.740 | $16.841 |
| General and administrative expense | $10.016 | $6.183 |
| Operating income | $18.985 | $9.029 |
| Net income | $34.438 | $9.627 |
| Net cash from operating activities | $20.179 | $10.653 |
- Revenue rose about 49%. FY2014 revenue comprised $40.0 million in AbbVie regulatory-filing milestones and $7.741 million under the NIAID contract. Enanta reported no product sales or royalties.
- Net income included a $15.170 million income-tax benefit, following release of the deferred-tax valuation allowance; it is not a recurring operating source of earnings. The company also recorded $40.0 million in AbbVie milestone revenue.
- Operating expenses increased about 25%, reflecting higher early-stage discovery and antibiotic-program costs and higher G&A, including stock-based compensation and public-company costs.
- Fourth-quarter FY2014 revenue was $2.637 million and net loss was $5.042 million, compared with revenue of $1.349 million and net loss of $4.443 million in fourth-quarter FY2013. The $40.0 million milestone and most of the tax benefit were recorded in the prior quarter.
- At September 30, 2014, cash, cash equivalents and marketable securities totaled $131.767 million; working capital was $103.229 million; total liabilities were $6.761 million. Enanta reported no debt. Management said existing resources were expected to fund anticipated cash needs for at least 24 months.
Material changes and developments
- AbbVie’s paritaprevir-containing HCV regimen applications had been accepted for U.S. and EU review; approval was not yet reported. Enanta cited expected U.S. approval by late December 2014 and EU approval in early 2015.
- In October 2014, Enanta amended its AbbVie agreement to establish the portions of combination-regimen net sales allocated to its compounds for royalty calculations: paritaprevir allocations are 30% for a three-DAA regimen and 45% for a two-DAA regimen; ABT-493 allocations are 33⅓% and 50%, respectively, subject to further adjustment in specified circumstances. Royalties are tiered and subject to contractual reductions and limits.
- In September 2014, Novartis returned full rights to EDP-239 and Enanta’s NS5A program. Enanta assumed responsibility for transitioning an ongoing proof-of-concept study and will fund future development itself.
- In December 2014, Enanta decided to stop commercial development of its antibiotic program for non-biodefense indications and expected NIAID to terminate its funding contract for convenience.
Outlook, risks and unusual items
- Management expected most of up to $155 million in additional pre-commercialization milestones under the AbbVie agreement to be earned in FY2015 if regulatory approvals were obtained. Timing and receipt are uncertain; royalties depend on commercial sales and contractual net-sales allocations.
- Enanta expected R&D and G&A expenses to rise as it advances independent programs. It estimated that an NDA for a product other than paritaprevir was unlikely to be approved before approximately FY2018.
- Key risks include dependence on AbbVie’s decisions and execution; competition from rapidly advancing HCV therapies; clinical, regulatory, reimbursement and commercialization uncertainty; reliance on third-party manufacturers and research contractors; intellectual-property challenges; and the possibility of needing additional financing if collaboration proceeds or payments fall short.
- FY2014 earnings were materially affected by milestone revenue and the tax valuation-allowance reversal. The company has an accumulated deficit of $73.012 million and no recurring product revenue. NIAID contract revenue and any associated termination settlement remain subject to contract terms, funding, and review.
Important facts for investors to verify
- Whether and when AbbVie’s paritaprevir regimen obtained regulatory approval, and the resulting milestone payments and launch progress.
- Actual sales, royalty-bearing allocations, royalty rates, and any contractual royalty reductions for paritaprevir or ABT-493 regimens.
- EDP-239 transition status, clinical progress, and Enanta’s resulting development costs and financing needs.
- Whether NIAID terminated the antibiotic contract and the final funding or settlement outcome.
- Cash use and runway relative to management’s 24-month estimate, given planned increases in independent R&D spending and the absence of product-sale revenue.